Nanopublications

Matches in Nanopublications for { ?s ?p "[Particularly, ER?, PR, hMLH1, CDKN2A/P16, SFRP1, SFRP2 and SFRP5 revealed a promoter methylation status in endometrioid carcinoma, whereas SFRP4 showed demethylation in cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

Showing items 1 to 16 of 16 with 100 items per page.

NP874028.RADWD6YCTBQAVYud-pAcJJ8RAld3G3QvZdfrASx6zgHd8130_assertion description "[Particularly, ER?, PR, hMLH1, CDKN2A/P16, SFRP1, SFRP2 and SFRP5 revealed a promoter methylation status in endometrioid carcinoma, whereas SFRP4 showed demethylation in cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP874028.RADWD6YCTBQAVYud-pAcJJ8RAld3G3QvZdfrASx6zgHd8130_provenance.
NP550218.RARqr74ed_l1eWwWrjRpCRWhOJtELDcnoUO6E9dBpKytA130_assertion description "[Particularly, ER?, PR, hMLH1, CDKN2A/P16, SFRP1, SFRP2 and SFRP5 revealed a promoter methylation status in endometrioid carcinoma, whereas SFRP4 showed demethylation in cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP550218.RARqr74ed_l1eWwWrjRpCRWhOJtELDcnoUO6E9dBpKytA130_provenance.
NP614962.RAaEafo8wTmGyiYT1bXZb60gR9xIti9QAbIXZYvXazbes130_assertion description "[Particularly, ER?, PR, hMLH1, CDKN2A/P16, SFRP1, SFRP2 and SFRP5 revealed a promoter methylation status in endometrioid carcinoma, whereas SFRP4 showed demethylation in cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP614962.RAaEafo8wTmGyiYT1bXZb60gR9xIti9QAbIXZYvXazbes130_provenance.
NP656855.RAUUhxzKQxO5OOJtLTdE5aT09OcI1np7sRuTtzLQi6JWI130_assertion description "[Particularly, ER?, PR, hMLH1, CDKN2A/P16, SFRP1, SFRP2 and SFRP5 revealed a promoter methylation status in endometrioid carcinoma, whereas SFRP4 showed demethylation in cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP656855.RAUUhxzKQxO5OOJtLTdE5aT09OcI1np7sRuTtzLQi6JWI130_provenance.
NP156037.RAknXZgzpBfjR7y_YZkKifIsRAdHhomJ-5zUu_hAHoCmk130_assertion description "[Particularly, ER?, PR, hMLH1, CDKN2A/P16, SFRP1, SFRP2 and SFRP5 revealed a promoter methylation status in endometrioid carcinoma, whereas SFRP4 showed demethylation in cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP156037.RAknXZgzpBfjR7y_YZkKifIsRAdHhomJ-5zUu_hAHoCmk130_provenance.
NP615183.RAqBry1B_GoW0UmTKCH5mRmGnqU1HtFYwstPDRnaOgMLw130_assertion description "[Particularly, ER?, PR, hMLH1, CDKN2A/P16, SFRP1, SFRP2 and SFRP5 revealed a promoter methylation status in endometrioid carcinoma, whereas SFRP4 showed demethylation in cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP615183.RAqBry1B_GoW0UmTKCH5mRmGnqU1HtFYwstPDRnaOgMLw130_provenance.
NP674309.RAfL7wduOYMpIyvL2LKntqcDCKAwgGmNfe3R_T7rX2Rps130_assertion description "[Particularly, ER?, PR, hMLH1, CDKN2A/P16, SFRP1, SFRP2 and SFRP5 revealed a promoter methylation status in endometrioid carcinoma, whereas SFRP4 showed demethylation in cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP674309.RAfL7wduOYMpIyvL2LKntqcDCKAwgGmNfe3R_T7rX2Rps130_provenance.
NP866969.RAf7R6gY5dfeEPheur_pKyMLAE_kfKYgNGgcBuBCYhzB4130_assertion description "[Particularly, ER?, PR, hMLH1, CDKN2A/P16, SFRP1, SFRP2 and SFRP5 revealed a promoter methylation status in endometrioid carcinoma, whereas SFRP4 showed demethylation in cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP866969.RAf7R6gY5dfeEPheur_pKyMLAE_kfKYgNGgcBuBCYhzB4130_provenance.
NP375577.RAPDex2SRCQbjixedgccC3CX1sxKl96CLIwfX1vfYCTzg130_assertion description "[Particularly, ER?, PR, hMLH1, CDKN2A/P16, SFRP1, SFRP2 and SFRP5 revealed a promoter methylation status in endometrioid carcinoma, whereas SFRP4 showed demethylation in cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP375577.RAPDex2SRCQbjixedgccC3CX1sxKl96CLIwfX1vfYCTzg130_provenance.
NP691285.RAaHHvnPiI1_3T65TORmFGC1GOlRJaBqTmfUz-BvN25mw130_assertion description "[Particularly, ER?, PR, hMLH1, CDKN2A/P16, SFRP1, SFRP2 and SFRP5 revealed a promoter methylation status in endometrioid carcinoma, whereas SFRP4 showed demethylation in cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP691285.RAaHHvnPiI1_3T65TORmFGC1GOlRJaBqTmfUz-BvN25mw130_provenance.
assertion description "[Particularly, ER?, PR, hMLH1, CDKN2A/P16, SFRP1, SFRP2 and SFRP5 revealed a promoter methylation status in endometrioid carcinoma, whereas SFRP4 showed demethylation in cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
NP690785.RAgM7_lrJZGr4RerYoohvv0bktj78ww1nFZouvadgqPnA130_assertion description "[Particularly, ER?, PR, hMLH1, CDKN2A/P16, SFRP1, SFRP2 and SFRP5 revealed a promoter methylation status in endometrioid carcinoma, whereas SFRP4 showed demethylation in cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP690785.RAgM7_lrJZGr4RerYoohvv0bktj78ww1nFZouvadgqPnA130_provenance.
NP691007.RAkiIB848KhwdrztHFt_HpLEwrdwG8ajx_5AwjZfHXTlY130_assertion description "[Particularly, ER?, PR, hMLH1, CDKN2A/P16, SFRP1, SFRP2 and SFRP5 revealed a promoter methylation status in endometrioid carcinoma, whereas SFRP4 showed demethylation in cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP691007.RAkiIB848KhwdrztHFt_HpLEwrdwG8ajx_5AwjZfHXTlY130_provenance.
NP691184.RAkfjWl-NTD-OAyOBq8iwZZQniNtK45KlZehRJqHiIwhA130_assertion description "[Particularly, ER?, PR, hMLH1, CDKN2A/P16, SFRP1, SFRP2 and SFRP5 revealed a promoter methylation status in endometrioid carcinoma, whereas SFRP4 showed demethylation in cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP691184.RAkfjWl-NTD-OAyOBq8iwZZQniNtK45KlZehRJqHiIwhA130_provenance.
NP691235.RA1KlWW4TVIdonCYwcJel-i1BMY4It6BCClQmIeSOi41Y130_assertion description "[Particularly, ER?, PR, hMLH1, CDKN2A/P16, SFRP1, SFRP2 and SFRP5 revealed a promoter methylation status in endometrioid carcinoma, whereas SFRP4 showed demethylation in cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP691235.RA1KlWW4TVIdonCYwcJel-i1BMY4It6BCClQmIeSOi41Y130_provenance.
NP905432.RA5GyBdJP4IKiyqDQ_Je6IWvinxWbYeiL6LqHkKJbayoo130_assertion description "[Particularly, ER?, PR, hMLH1, CDKN2A/P16, SFRP1, SFRP2 and SFRP5 revealed a promoter methylation status in endometrioid carcinoma, whereas SFRP4 showed demethylation in cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP905432.RA5GyBdJP4IKiyqDQ_Je6IWvinxWbYeiL6LqHkKJbayoo130_provenance.